×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
PVLA – palvella therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
PVLA
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/16
12:28 pm
pvla
Palvella Therapeutics (NASDAQ:PVLA) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $192.00 price target on the stock.
Low
Report
Palvella Therapeutics (NASDAQ:PVLA) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $192.00 price target on the stock.
1/12
06:12 am
pvla
Assessing Palvella Therapeutics (PVLA) Valuation After Strong One Year Returns And Conflicting Signals [Yahoo! Finance]
Medium
Report
Assessing Palvella Therapeutics (PVLA) Valuation After Strong One Year Returns And Conflicting Signals [Yahoo! Finance]
1/9
09:17 am
pvla
Palvella Therapeutics Provides Corporate Update and 2026 Outlook: Advancing a Late Clinical-Stage Pipeline and Platform to Address Multiple Serious, Rare Skin Diseases and Vascular Malformations with No FDA-Approved Therapies [Yahoo! Finance]
Medium
Report
Palvella Therapeutics Provides Corporate Update and 2026 Outlook: Advancing a Late Clinical-Stage Pipeline and Platform to Address Multiple Serious, Rare Skin Diseases and Vascular Malformations with No FDA-Approved Therapies [Yahoo! Finance]
1/9
07:30 am
pvla
Palvella Therapeutics Provides Corporate Update and 2026 Outlook: Advancing a Late Clinical-Stage Pipeline and Platform to Address Multiple Serious, Rare Skin Diseases and Vascular Malformations with No FDA-Approved Therapies
Medium
Report
Palvella Therapeutics Provides Corporate Update and 2026 Outlook: Advancing a Late Clinical-Stage Pipeline and Platform to Address Multiple Serious, Rare Skin Diseases and Vascular Malformations with No FDA-Approved Therapies
1/7
08:02 am
pvla
Palvella Therapeutics (NASDAQ:PVLA) is now covered by analysts at Mizuho. They set an "outperform" rating and a $205.00 price target on the stock.
Medium
Report
Palvella Therapeutics (NASDAQ:PVLA) is now covered by analysts at Mizuho. They set an "outperform" rating and a $205.00 price target on the stock.
1/7
07:30 am
pvla
Palvella Therapeutics Strengthens Leadership Team with Appointment of Veteran Medical Affairs Leader Vimal Patel, PharmD, as Senior Vice President of Medical Affairs
Medium
Report
Palvella Therapeutics Strengthens Leadership Team with Appointment of Veteran Medical Affairs Leader Vimal Patel, PharmD, as Senior Vice President of Medical Affairs
12/23
10:44 am
pvla
Palvella Therapeutics: Phase 2 Success De-Risks 2026 Catalyst [Seeking Alpha]
Medium
Report
Palvella Therapeutics: Phase 2 Success De-Risks 2026 Catalyst [Seeking Alpha]
12/21
07:42 am
pvla
High Analyst Confidence on Palvella Therapeutics (PVLA) Following Encouraging Phase 2 Data for QTORIN Rapamycin [Yahoo! Finance]
Medium
Report
High Analyst Confidence on Palvella Therapeutics (PVLA) Following Encouraging Phase 2 Data for QTORIN Rapamycin [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
11/11/2025
07:30 am
PVLA
palvella therapeutics, inc.
MISS
Report
-4.6%
palvella therapeutics, inc.
8/14/2025
07:30 am
PVLA
palvella therapeutics, inc.
MISS
Report
3.9%
palvella therapeutics, inc.
5/15/2025
07:30 am
PVLA
palvella therapeutics, inc.
BEAT
Report
4.6%
palvella therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
1/12
07:01 am
pvla
Form 8-K PALVELLA THERAPEUTICS, For: Jan 12
Medium
Report
Form 8-K PALVELLA THERAPEUTICS, For: Jan 12
1/2
07:30 am
pvla
Form S-3 PALVELLA THERAPEUTICS,
Medium
Report
Form S-3 PALVELLA THERAPEUTICS,
12/19
04:05 pm
pvla
Form 4 PALVELLA THERAPEUTICS, For: Dec 17 Filed by: Goin Kathleen
Medium
Report
Form 4 PALVELLA THERAPEUTICS, For: Dec 17 Filed by: Goin Kathleen
12/17
04:33 pm
pvla
Form 144 PALVELLA THERAPEUTICS, Filed by: Goin Kathleen
Medium
Report
Form 144 PALVELLA THERAPEUTICS, Filed by: Goin Kathleen
12/15
06:06 am
pvla
Form 8-K PALVELLA THERAPEUTICS, For: Dec 15
High
Report
Form 8-K PALVELLA THERAPEUTICS, For: Dec 15
11/21
04:25 pm
pvla
Form 4 PALVELLA THERAPEUTICS, For: Nov 19 Filed by: Goin Kathleen
Medium
Report
Form 4 PALVELLA THERAPEUTICS, For: Nov 19 Filed by: Goin Kathleen
11/19
04:47 pm
pvla
Form 144 PALVELLA THERAPEUTICS, Filed by: Goin Kathleen
Medium
Report
Form 144 PALVELLA THERAPEUTICS, Filed by: Goin Kathleen
11/14
04:26 pm
pvla
Form SCHEDULE 13G/A PALVELLA THERAPEUTICS, Filed by: BIOTECHNOLOGY VALUE FUND L P
Low
Report
Form SCHEDULE 13G/A PALVELLA THERAPEUTICS, Filed by: BIOTECHNOLOGY VALUE FUND L P
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: